KEGG   DRUG: D09588Help
Entry
D09588                      Drug                                   

Name
Briakinumab (USAN/INN)
Formula
C6376H9874N1722O1992S44
Exact mass
143845.1988
Mol weight
143933.825
Sequence
(Heavy chain) QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYGMHWVRQA
PGKGLEWVAF IRYDGSNKYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCKTHG
SHDNWGQGTM VTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE PVTVSWNSGA
LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTQTYICNV NHKPSNTKVD KKVEPKSCDK
THTCPPCPAP ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV
EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ
PREPQVYTLP PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG
SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK
(Disulfide bridge: 22-96; 142-198; 259-319; 65-423, Dimer: 224; 227)
(Light chain) QSVLTQPPSV SGAPGQRVTI SCSGSRSNIG SNTVKWYQQL
PGTAPKLLIY YNDQRPSGVP DRFSGSKSGT SASLAITGLQ AEDEADYYCQ SYDRYTHPAL
LFGTGTKVTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT VAWKADSSPV
KAGVETTTPS KQSNNKYAAS SYLSLTPEQW KSHRSYSCQV THEGSTVEKT VAPTECS
(Disulfide bridge: 22-89; 139-198, H218-L216)
  Type
Peptide
Activity
Treatment of autoimmune disorders
Remark
ATC code: 
Comment
Monoclonal antibody
Target
interleukin 12 [HSA:3592 3593] [KO:K05406 K05425];
interleukin 23 [HSA:51561] [KO:K05426]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04630  Jak-STAT signaling pathway  
 
Interaction
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AC Interleukin inhibitors
     L04AC09 Briakinumab
      D09588  Briakinumab (USAN/INN)
Target-based classification of drugs [BR:br08310]
 Cytokines
  Class I cytokines
   IL-12
    Briakinumab
     D09588  Briakinumab (USAN/INN)
   IL-23
    Briakinumab
     D09588  Briakinumab (USAN/INN)
BRITE hierarchy
Other DBs
CAS: 
339308-60-0
PubChem: 

» Japanese version   » Back

DBGET integrated database retrieval system